NC-6004 + pembrolizumab

**NC-6004 + pembrolizumab** is an investigational combination therapy consisting of **NC-6004**, a micellar nanoparticle formulation of cisplatin, and **pembrolizumab**, a monoclonal antibody targeting the programmed death 1 (PD-1) receptor. NC-6004 is designed for sustained release and selective tumor distribution of cisplatin, offering improved tolerability (lower nephrotoxicity and neurotoxicity) compared to conventional cisplatin[6]. Pembrolizumab functions as an immune checkpoint inhibitor, augmenting anti-tumor immunity by blocking the PD-1 receptor. This combination is primarily being studied for recurrent or metastatic squamous cell carcinoma of the head and neck in patients who have failed platinum-based regimens, with active multi-center phase II trials ongoing[5][8].

Other names

Keytrudananoparticle cisplatin + pembrolizumab